THE SELECTIVITY AND SPECIFICITY OF THE ACTIONS OF THE LIPIDO-STEROLIC EXTRACT OF SERENOA REPENS (PERMIXON®) ON THE PROSTATE
2000; Lippincott Williams & Wilkins; Volume: 164; Issue: 3 Part 1 Linguagem: Inglês
10.1016/s0022-5347(05)67330-2
ISSN1527-3792
AutoresColin W. Bayne, Margaret Ross, Frank Donnelly, Fouad K. Habib,
Tópico(s)Sperm and Testicular Function
ResumoNo AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Sep 2000THE SELECTIVITY AND SPECIFICITY OF THE ACTIONS OF THE LIPIDO-STEROLIC EXTRACT OF SERENOA REPENS (PERMIXON®) ON THE PROSTATE COLIN W. BAYNE, MARGARET ROSS, FRANK DONNELLY, and FOUAD K. HABIB COLIN W. BAYNECOLIN W. BAYNE , MARGARET ROSSMARGARET ROSS , FRANK DONNELLYFRANK DONNELLY , and FOUAD K. HABIBFOUAD K. HABIB View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67330-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To investigate the effects of the phytotherapeutic agent, Permixon®, on primary cultures of fibroblast and epithelial cells from the prostate, epididymis, testes, kidney, skin and breast and to determine the selectivity and specificity of the action of the drug. Materials and Methods: All primary cultures were examined by electron microscopy before and following treatment with Permixon® (10 μg./ml.). In addition the apoptotic index was assessed by flow cytometry employing propidium iodide as a fluorophore. The impact of the drug on 5α-reductase (5αR) isoenzymes was also tested utilizing a pH specific assay. Results: There were changes in the morphology of prostate cells after treatment including accumulation of lipid in the cytoplasm and damage to the nuclear and mitochondrial membranes; no similar changes were observed in other cells. Permixon® increased the apoptotic index for prostate epithelial cells by 35% and 12% in the prostate stromal/fibroblast. A lesser apoptotic effect was demonstrated in skin fibroblast (3%) whereas none of the other primary cultures showed any increase in apoptosis when compared with the controls. Permixon® was also an effective inhibitor of both 5αR type I and II isoenzymes in prostate cells, but other cells showed no inhibition of 5αR activity following treatment with the plant extract. Conclusions: This investigation demonstrated the selectivity of the action of Permixon® for prostate cells. The morphological changes in the prostate are accompanied by an increase in the apoptotic index along with an inhibition in the activity of the nuclear membrane bound 5αR isoenzymes. No similar changes were observed in any of the other cells under investigation. References 1 : Phytotherapy for the prostate. Br J Urol1996; 78: 325. Google Scholar 2 : Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Ageing1996; 9: 379. Google Scholar 3 : Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp de Urol1995; 40: 97. Google Scholar 4 : Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomised international study of 1098 patients. Prostate1996; 29: 231. Google Scholar 5 : Saw Palmetto extracts for treatment of benign prostatic hyperplasia. JAMA1998; 280: 1604. Google Scholar 6 : Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Adult Urology2000; 55. in press. Google Scholar 7 : Human prostatic steroid 5α-reductase isoforms. A comparative study of selective inhibitors. J. Steroid Biochem Mol Biol1995; 54: 273. Google Scholar 8 : Serenoa repens (Permixon®): a 5α-reductase types I and II inhibitor–new evidence in a coculture model of BPH. Prostate1999; 40: 232. Google Scholar 9 : Effects of long term treatment with the n-hexane lipido-sterolic extract of Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate1998; 37: 77. Google Scholar 10 : Binding of Permixon: a new treatment for prostatic benign hyperplasia to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem Mol Biol1984; 20: 521. Google Scholar 11 : Effect of the lipido-sterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol1997; 33: 340. Google Scholar 12 : Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate1996; 29: 231. Google Scholar 13 : Placebo controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest1995; 5: 291. Google Scholar 14 : Meta-analysis of clinical trials of Permixon. [Abstract] J Urol1998; 159: 257. Google Scholar 15 : Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res1996; 24: 265. Google Scholar 16 : Regulation of prostate growth in culture with the pollen extract, cernitin T-60 and the impact of the drug on the EGF tissue profiles. In: . Stuttgart; New York: Thieme Verlag1992: 120. Google Scholar 17 : Structural features of rat epididymal epithelial cells in vitro. J Reprod Fertil1985; 75: 401. Google Scholar 18 : Primary culture of prepubertal human testicular cells isolated from testes collected at necropsy. Acta Endocrinol1992; 127: 66. Google Scholar 19 : The lower radiosensitivity of mouse kidney cells irradicated in vivo then in vitro: a cell contact effect phenomenon. Int J Rad Oncol Biol Phys1996; 20: 1243. Google Scholar 20 : Cultured human skin fibroblasts: a model for the study of androgen action. Mol Cell Biochem1981; 36: 3. Google Scholar 21 : Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res1998; 17: 19. Google Scholar 22 : Improved procedures for electron microscopic visualisation of the cytoskeleton of cultured cells. J Struct Biol1995; 115: 290. Google Scholar 23 : A novel co-culture model for benign prostatic hyperplasia expressing both isoforms of 5α-reductase. J Clin Endocrinol Metab1998; 83: 206. Google Scholar 24 : 5α-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia. J Clin Endocrinol Metab1996; 81: 1361. Google Scholar 25 : Partial purification of human 5α-reductase (3-oxo-5α steroid: NAD+ 4-ene-oxide-reductase; EC1.3.1.22) in a stable and active form. J Steroid Biochem Mol Biol1991; 38: 73. Google Scholar 26 : Fatty acid composition of phospholipids in epithelium and stroma of human benign prostatic hyperplasia. Prostate1998; 36: 235. Google Scholar 27 : Phospholipid requirement of 5α-reductase in human benign prostatic hyperplasia (BPH). Urol Res1997; 25: 73A. Google Scholar 28 : Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate1996; 29: 219. Google Scholar 29 : Distribution study of radiolabelled activity in rats after oral administration of lipidosterolic extract of Serenoa repens (Permixon®) supplemented with [114C] lauric acid, [114C] Oleic acid or [414C] β-sitosterol. Eur J Drug MetabPharmacokinetics1997; 22: 73. Google Scholar 30 : The insulin-like growth factor type I receptor stimulates growth and suppressed apoptosis in prostatic stromal cells. J Clin Endocr Metab1998; 83: 3252. Google Scholar 31 : Ductal heterogeneity of cytokeratines gene expression and cell death in the rat ventral prostate. Mol Endocrinol1990; 4: 2003. Google Scholar From the Prostate Research Group, University Department of Oncology, and the University Department of Pathology, Western General Hospital, Edinburgh, Scotland, United Kingdom© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byVELA-NAVARRETE R, ESCRIBANO-BURGOS M, FARRÉ A, GARCÍA-CARDOSO J, MANZARBEITIA F and CARRASCO C (2018) SERENOA REPENS TREATMENT MODIFIES BAX/BCL-2 INDEX EXPRESSION AND CASPASE-3 ACTIVITY IN PROSTATIC TISSUE FROM PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 173, NO. 2, (507-510), Online publication date: 1-Feb-2005.BUCK A (2018) IS THERE A SCIENTIFIC BASIS FOR THE THERAPEUTIC EFFECTS OF SERENOA REPENS IN BENIGN PROSTATIC HYPERPLASIA? MECHANISMS OF ACTIONJournal of Urology, VOL. 172, NO. 5, (1792-1799), Online publication date: 1-Nov-2004. Volume 164Issue 3 Part 1September 2000Page: 876-881 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordscell morphologyPermixon®BPH5α-reductaseapoptosisMetricsAuthor Information COLIN W. BAYNE More articles by this author MARGARET ROSS More articles by this author FRANK DONNELLY More articles by this author FOUAD K. HABIB More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)